The National Heart, Lung and Blood Institute has awarded a nearly $5 million grant to the Johns Hopkins Children's Center for the establishment of a basic and translational research center that will consolidate research, treatment and care of adult and pediatric patients under one roof, speeding up the time between research and treatment.

"This center will be a marriage of all aspects of science and treatment, from basic science and clinical research to patient care and public health research, all part of the quest to treat and ultimately cure sickle cell disease," said lead investigator Dr. James F. Casella in a statement

A University of Adelaide researcher is embarking on a project that could help solve iron deficiency-the world's biggest nutritional deficiency problem.

According to a statement from the university, Dr. Alex Johnson has been awarded funds to work with the Bill Gates-funded HarvestPlus Challenge program. His research looks to increase the iron content in rice and other grains

Giving your infants too much iron which they do not need may delay their development, a study has found.

The study, led by Dr. Betsy Lozoff, University of Michigan research professor at the Centre for Human Growth and Development, leads a debate on the desirable level of iron supplements

The U.S. Food and Drug Administration (FDA) on Friday ordered drug maker Amgen to expand the black box warnings on the labels of Aranesp and other anemia drugs after it was linked to risks of death and tumor growth.

The drug, which is used to treat the blood-disorder anemia in patients with kidney failure and those on chemotherapy, has been found to accelerate tumor growth in patients with early stage breast cancer and cervical cancer. The changes apply to Thousand Oaks, Calif.-based Amgen's Aranesp and Epogen, as well as Johnson and Johnson's Procrit

GlaxoSmithKline PLC announced Friday that it will suspend development of its malaria drug Dacart and is recalling another drug, Lapdap, after it discovered the two drugs can lead to anemia.

Tests conducted by GSK and partner Medicines for Malaria Venture reveal both drugs lowered hemoglobin concentration in patients with hereditary enzyme deficiency disorders, which affects 10 to 25 percent of the sub-Saharan population in Africa